Reported Earlier, Daiichi Sankyo And AstraZeneca's ENHERTU Shows Progression-Free Survival To 13.2 Months In HR Positive, HER2 Low Metastatic Breast Cancer
Reported Earlier, Daiichi Sankyo And AstraZeneca's ENHERTU Shows Progression-Free Survival To 13.2 Months In HR Positive, HER2 Low Metastatic Breast Cancer
此前报道，第一三共和阿斯利康的ENHERTU显示，HR阳性、HER2低转移性乳腺癌的无进展存活率可达13.2个月
- DESTINY-Breast06 results show Daiichi Sankyo and AstraZeneca's ENHERTU is the first HER2 directed medicine and antibody drug conjugate to demonstrate clinically meaningful benefit for patients in this setting
- Additionally, data from DESTINY-Breast03 and DESTINY-Breast07 trials in HER2 positive metastatic breast cancer reinforce ENHERTU as standard of care in second-line setting and highlight potential in first-line setting
- Destiny-breast06结果显示，第一三共和阿斯利康的ENHERTU是第一种在这种环境下为患者显示出具有临床意义的益处的HER2定向药物和抗体药物偶联物
- 此外，来自针对HER2阳性转移性乳腺癌的Destiny-breast03和Destiny-breast07试验的数据强化了ENHERTU作为二线医疗标准的地位，也凸显了一线环境中的潜力